Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026
Basics
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Market cap
3.6B USD
Enterprise value
11.0B USD
Full-time employees
10,000
Overall health
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.54 vs a peer median of 0.63) and more debt relative to equity (8.50× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.54 vs peers 0.63) and more debt vs equity (8.50× vs peers 0.22×)
Ranks #777 of 1,157 healthcare companies (bottom 33%)
Much more borrowing than peers.Debt is 8.5× equity vs a peer median of 0.2×.Debt is 8.5× equity vs peers 0.2×.
Debt is 8.5× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 8.5× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Valuation signals disagree.Cheaper than 91% of peers on operating cash profit (EBITDA), but only 50% on free cash flow.Cheaper than 91% of peers on operating cash profit, but only 50% on free cash flow.
Relative to its operating cash profit (EBITDA), Organon looks cheaper than 91% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Organon looks cheaper than 91% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.
Cash flow well above reported profit. Free cash flow is 2.7× reported profit.
Free cash flow is 2.7× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Revenue is falling. Revenue fell 2.5% in the 12 months to June 2026 vs the 12 months before.
Organon's revenue fell 2.5% in the 12 months to June 2026 vs the 12 months before.
Return on invested capital, operating margin, and return on assets.
Operating margin19.7%
Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Reported value33% base weight · Z-score 1.04Sector median: 0.0706 · MAD: 0.1217
Return on assets1.6%
SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.01Sector median: 0.0166 · MAD: 0.0537
Return on invested capital11.9%
Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsReported value33% base weight · Z-score 0.72Sector median: 0.0471 · MAD: 0.1004
Other data (not scored)
Gross margin52.7%
SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310
Return on equity20.8%
SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Organon
Is Organon getting weaker?
Its latest SEC filing (Jul 31, 2026) showed no major changes. Its overall score is unchanged at 43/100 since Oct 28, 2026.
How is Organon valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 85/100 against 1,393 healthcare peers.EBITDA yield 14.1% vs a peer median of 4.0% (stronger than 91% of peers).EBITDA yield 14.1% vs peers 4.0% (stronger than 91% of peers).
Is Organon growing?
More slowly than most of its peers. Growth scores 15/100 against 1,393 healthcare peers.Earnings per share growth -70.4% vs a peer median of 9.8% (weaker than 96% of peers).Earnings per share growth -70.4% vs peers 9.8% (weaker than 96% of peers).
How profitable is Organon?
More profitable than most of its peers. Profitability scores 69/100 against 1,393 healthcare peers.Operating margin 19.7% vs a peer median of 7.1% (stronger than 80% of peers).Operating margin 19.7% vs peers 7.1% (stronger than 80% of peers).
How risky is Organon?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 8.50× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 8.50× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 31, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
6.2B USD
6.1B USD
−0.6%
Net income (12 months)
246.0M USD
209.0M USD
−15.0%
Free cash flow (12 months)
683.0M USD
567.0M USD
−17.0%
Debt
8.6B USD
8.6B USD
−0.2%
Cash
1.1B USD
1.1B USD
+1.4%
Shares outstanding
262.6M
262.6M
+0.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Drug Manufacturers - General companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
—
62.8%
59.8%
58.0%
53.3%
▼ 4.7 pts
Net margin
21.4%
14.9%
16.3%
13.5%
3.0%
▼ 10 pts
Return on assets (ROA)
12.6%
8.4%
8.5%
6.6%
1.5%
▼ 5.1 pts
Return on equity (ROE)
—
—
—
183.1%
24.9%
▼ 158 pts
Free cash flow margin
31.2%
10.7%
8.7%
11.9%
8.7%
▼ 3.3 pts
Current ratio
1.45×
1.56×
1.54×
1.60×
1.82×
▲ 14%
Quick ratio
1.10×
1.17×
1.09×
1.11×
1.23×
▲ 11%
Debt to equity
—
—
—
18.81×
11.49×
▼ 39%
OGN price history
Price history is added with the daily price update and will appear after the next one.